Latest Sales Pipeline News

Vitasora Health Limited has raised $11 million in a well-supported placement, positioning the company to achieve cash flow breakeven in the second half of FY2026. The capital injection underscores strong investor confidence following key contract expansions and operational milestones.

First Graphene Limited has secured two significant orders totaling approximately A$165,000 for its PureGRAPH graphene products, signaling growing market acceptance and supporting its FY25-26 sales outlook.

DroneShield Limited has reported a record-breaking first quarter in 2025, doubling its revenue year-over-year and nearly tripling its SaaS income, underpinned by a robust $2.41 billion sales pipeline and strong global defense spending.

Harvest Technology Group reports it is one year ahead of its 3-Year Pathway to Profit plan, forecasting a significant reduction in EBITDA loss for FY25 and unveiling plans for its AI-powered NEON platform launch in 1H26.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

Dubber Corporation has confirmed it will retain its key contract with Virgin Media O2, securing guaranteed revenues for FY26 while implementing significant cost reductions to return to cash flow positivity by year-end.

BetMakers Technology Group reports solid Q3 FY25 financial gains alongside a strategic binding agreement to acquire Nevada’s LVDC, expanding its global racing technology footprint.

UOA Development Bhd reported a striking surge in first quarter 2025 revenue and profit, driven by strong sales and ongoing project progress. The company’s robust unbilled sales pipeline signals sustained growth ahead.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.

Worley Limited has reaffirmed its FY25 financial outlook, targeting low double-digit EBITA growth and margins between 8-8.5%, supported by a robust $9.4 billion bookings pipeline and a strategic operational reorganisation.

Gentrack reported a solid 9.8% revenue increase to NZ$112 million in HY25, driven by recurring revenue growth and international expansion, while net profit after tax surged 34.7%. The company’s outlook remains optimistic as it targets FY25 revenue above NZ$230 million and deeper market penetration across Asia, Europe, and the Middle East.